Unlike small molecule drugs, biologi–cally derived products are large, com–plex molecules, requiring a battery of analytical techniques, chemical and instrumental for their structural analysis. Biosimilar molecules face comparable challenges in their characterization. Interested in learning more?
Download the white paper Biosimilar Development: From Science to Market, which provides a comprehensive overview of the regulatory hurdles and characterization challenges of developing a Biosimilar product.
Register to attend the webinar: Biosimilars: Structural Characterization and Comparability Approaches, which describes how to approach biosimilar characterization and comparability to originator molecules.
Date: October 19, 2011
Place: SGS Life Science Services, Wavre, Belgium
If you’re not able to attend, you can still download
our latest white paper on Protein and Glycoprotein Characterization by Mass Spectrometry. |
SGS SA